

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **CanSino Biologics Inc.**

## **康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

### **INSIDE INFORMATION**

### **FINANCIAL INFORMATION IN RELATION TO A SHARE PROSPECTUS**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the Company’s announcement dated October 14, 2019, circular dated October 14, 2019 and supplemental circular dated November 14, 2019 containing, among other things, related matters of the proposed initial public issue of A Shares (the “**Proposed Issue of A Shares**”) and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (the “**Shanghai Stock Exchange**”).

The full text of the prospectus in relation to the Proposed Issue of A Shares (the “**A Share Prospectus**”) has been published on the website of the Review and Approval of the Issuance and Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange at (kcb.sse.com.cn), and will be published on the website of the Stock Exchange at (www.hkexnews.hk) and the website of the Company at (www.cansinotech.com) on the same date pursuant to Rule 13.10B of the Listing Rules.

The summary of the financial statements (the “**Financial Statements**”) of the Company for the nine months ended September 30, 2019 of the Company is set out in “Section VIII – Financial Information and Management Analysis” in the A Share Prospectus. The Financial Statements are prepared in accordance with the Chinese Accounting Standards for Business Enterprises and have been audited by PricewaterhouseCoopers Zhong Tian LLP.

The key financial data of the Company's balance sheet as at September 30, 2019, statement of profit or loss and statement of cash flows for the nine months ended September 30, 2019 are as follows:

*Unit: RMB'000*

<b>Item</b>	<b>As at September 30, 2019</b>
Total assets	1,829,962
Total liabilities	300,881
Total shareholder's equity	1,529,081
Total liabilities and shareholder's equity	1,829,962

<b>Item</b>	<b>Nine months ended September 30, 2019</b>
Operating income	1,930
Operating loss	(98,766)
Total losses	(93,474)
Net losses	(93,474)
Net cash flows used in operating activities	(96,047)
Net cash flows used in investing activities	(955,726)
Net cash flows generated from financing activities	1,100,297
Effect of changes in exchange rate on cash and cash equivalents	24,937
Net increase in cash and cash equivalents	73,461
Balance of cash and cash equivalents at the beginning of the period	57,374
Balance of cash and cash equivalents at the end of the period	130,835

The above English version of the summary of the Financial Statements of the Company is an unofficial translation of its Chinese version. In case of any discrepancies, the Chinese version shall prevail.

**As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the H shares of the Company. Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.**

By Order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, February 3, 2020

*As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.*